STOCK TITAN

Lantern Pharma Inc - LTRN STOCK NEWS

Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.

Lantern Pharma Inc. (LTRN) leverages artificial intelligence and precision medicine to revolutionize oncology drug development. This news hub provides investors and researchers with timely updates on the company's progress in transforming cancer treatment through biomarker-driven approaches.

Access centralized, reliable information on clinical trial milestones, strategic collaborations, and regulatory developments. Our curated news collection simplifies tracking of AI-powered drug discovery advancements and therapeutic pipeline updates specific to Lantern Pharma's innovative platform.

Discover how machine learning accelerates oncology research while maintaining focus on genetic screening precision. The page serves as an essential resource for understanding the company initiatives shaping personalized cancer therapies.

Bookmark this page for streamlined access to verified announcements and analysis-free updates directly impacting Lantern Pharma's position in biotechnology innovation.

Rhea-AI Summary

Lantern Pharma has received a Certificate of Patent from the Japanese Patent Office (JPO) for its drug candidate LP-284, developed using the company's RADR® AI platform. LP-284, aimed at treating relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas, is currently in a Phase 1 clinical trial. Japan is the third country to issue this patent, following the US in April 2023, with anticipated patents in Europe, China, and other countries. Lantern estimates LP-284 could benefit 40,000 to 80,000 blood cancer patients annually, potentially capturing a $4 billion global market. The drug has also received Orphan Drug Designation from the U.S. FDA for the treatment of high-grade B-cell lymphomas and mantle cell lymphoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
none
-
Rhea-AI Summary

Lantern Pharma Inc. (NASDAQ: LTRN) released its first-quarter 2024 financial results and operational highlights. The company reported progress in multiple clinical trials, obtaining regulatory allowance for the Harmonic™ clinical trial in Japan and Taiwan, and advancing AI-guided drug candidates LP-184 and LP-284. The global market potential for LP-184 and LP-284 is estimated to exceed $12 billion USD. Additionally, collaborations with Starlight Therapeutics and Oregon Therapeutics aim to streamline drug development strategies and leverage AI technologies. The company is focused on precision oncology and the development of high-impact drug candidates, reflecting a positive outlook for future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
-
Rhea-AI Summary

Oregon Therapeutics and Lantern Pharma are collaborating to optimize the development of the first-in-class drug candidate XCE853, a potent inhibitor of cancer metabolism. The collaboration involves leveraging AI to refine and expand the positioning of XCE853 in new oncology indications, aiming to uncover biomarkers and define potential combination regimens. Lantern Pharma will have equal IP co-ownership and drug development rights in newly discovered biomarkers and indications for XCE853.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.38%
Tags
AI
Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) will host a webcast on May 9th, 2024, discussing their first quarter 2024 financial results, upcoming milestones, clinical trials, and developments of their AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO. Register for the webinar here and access the replay on the investor relations section of the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
conferences earnings
-
Rhea-AI Summary
Lantern Pharma, Inc. (NASDAQ: LTRN) has launched 'Webinar Wednesdays' featuring top physician scientists and key opinion leaders discussing critical areas of oncology drug development. The webinars are set to be held monthly, starting on April 24th, 2024, with the first session focusing on non-small cell lung cancer and the LP-300 drug candidate. Subsequent sessions will cover pancreatic cancer and the LP-184 drug candidate, with renowned collaborators like Dr. Joseph Treat and Dr. Igor Astsaturov participating.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
none
-
Rhea-AI Summary
Lantern Pharma, a NASDAQ-listed AI company, gets approval to expand the Harmonic™ clinical trial for non-small cell lung cancer in never-smokers to Japan and Taiwan. Dr. Yashushi Goto will lead the trial, aiming to provide a therapeutic option for patients in East Asia, where lung cancer in never-smokers is prevalent. The unique mechanism of action of LP-300 targets distinct mutations in these patients, potentially revolutionizing treatment for this growing patient segment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. The company is actively engaged in multiple clinical trials for AI-guided drug candidates, with first data expected in the second half of 2024. Lantern Pharma has dosed initial patients in Phase 1 clinical trials for synthetic lethal drug-candidates LP-184 and LP-284, expanded Phase 2 LP-300 Harmonic™ clinical trial, and advanced Starlight Therapeutics towards a potential Phase 1B/2 clinical trial. The company exceeded its 2023 goal for oncology drug development AI platform RADR® and aims to achieve a 100 billion datapoint goal for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.8%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces dosing of first two patients in Phase 1 clinical trial for LP-284, a potential therapy for non-Hodgkin’s lymphoma and solid tumors. LP-284 is the second synthetic-lethal molecule from Lantern, with AI playing a crucial role. The drug has the potential to benefit 40,000 to 80,000 patients annually, with a global market potential of $4 billion USD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2023 financial results, along with upcoming milestones, clinical trials, and developments of its AI platform, RADR®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.58%
Tags
conferences earnings
Rhea-AI Summary
Lantern Pharma (NASDAQ: LTRN) will present at a virtual conference hosted by HCW on March 7th. CEO Panna Sharma will discuss AI-driven cancer drug discovery. Investors can register for the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences
Lantern Pharma Inc

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

33.54M
9.20M
14.72%
23.34%
2.15%
Biotechnology
Pharmaceutical Preparations
Link
United States
DALLAS